Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px
Document › Details

Kinaxo Biotechnologies GmbH. (1/12/10). "Press Release: Kinaxo Extends Its Collaboration with Roche". Martinsried.

Region Region Germany
Organisations Organisation Kinaxo Biotechnologies GmbH
  Today Evotec (München) GmbH
  Group Evotec (Group)
  Organisation 2 Roche Diagnostics GmbH, Penzberg
  Group Roche (Group)
Products Product PhosphoScout® technology
  Product 2 drug development services

KINAXO Biotechnologies GmbH announced today that it has entered into a second collaboration with Roche Diagnostics GmbH in Penzberg, Germany. Under the agreement KINAXO will apply its phosphoproteomics technology PhosphoScout® to support targeted treatment approaches currently under development at Roche. Financial details of the agreement were not disclosed.

KINAXO's phosphoproteomics platform PhosphoScout® enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase inhibitor treatment. Using state-of-the-art quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, thereby facilitating analysis of the phosphoproteome in patient samples, animal models and cell culture on a global scale. Unlike immunoassays, PhosphoScout® does not require antibodies for detection, thus enabling unbiased, comprehensive phosphoproteome analyses across entire signaling pathways. This positions PhosphoScout® as an upcoming technology for drug mode of action analysis and the stratification of cancer patients receiving targeted therapies.


KINAXO Biotechnologies is a privately-held biotechnology service company based in Munich/Martinsried, Germany. KINAXO offers extensive experience in chemical proteomics and quantitative phosphoproteomics technologies for drug mode-of-action analysis, cellular target profiling, target deconvolution, and drug re-positioning.

KINAXO just completed a financing round and recently announced its collaboration with Bayer Vital GmbH for biomarker development, as well as renewing its ongoing agreement with Johnson & Johnson.

Record changed: 2014-04-23


Picture [LSA] – The Business Web Portal 650x89px

More documents for Evotec (Group)

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to and simply fill the subject line with the word »MSC Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at and


Picture EBD Group BioTech Showcase 2020 San Francisco BEU2020 650x76px

» top